<DOC>
	<DOC>NCT00151762</DOC>
	<brief_summary>This extension study is designed to evaluate the long-term safety and tolerability of colesevelam hydrochloride (WelChol®) in patients with type 2 diabetes.</brief_summary>
	<brief_title>Long-Term Study of Safety and Efficacy of WelChol® as an Additional Therapy in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<criteria>Inclusion/Rollover Criteria: Patients who have completed studies WEL301, WEL302, or WEL303 with treatment compliance at least 80% Patients who have completed studies WEL301, WEL302, or WEL303 who have not met withdrawal criteria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Open label, Diabetes Mellitus</keyword>
	<keyword>Long term safety study, extension study</keyword>
</DOC>